- Ongoing, recruitingTherapeutic confirmatory (Phase III)
INCB 18424-319: A phase 3, double-blind, randomised, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with Purigo Nodularis. Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN1)
This study is testing a new cream for Prurigo Nodularis, a skin condition causing very itchy bumps. It compares a cream with the active medicine to a plain cream, to see if the new medicine can help reduce itchiness and improve the skin condition over 12 weeks.
For: Prurigo NodularisSpain · Italy · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo
This study is testing a new cream called ruxolitinib for people with vitiligo on their genitals. It's looking at how safe and effective the cream is at helping the skin colour return to normal over nearly a year by making white patches less noticeable or disappear.
For: Nonsegmental vitiligo with genital involvementFrance - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
This study is looking at a cream called ruxolitinib for children aged 6 to 11 with a skin condition called nonsegmental vitiligo. Researchers want to see how well it works to reduce white patches and if it's safe to use.
For: NonSegmental VitiligoArgentina · Austria · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
This study is testing a new cream called ruxolitinib for adults with ongoing hand eczema. It compares the new cream to a dummy cream to see how well it works and if it's safe over 16 weeks, with a longer open-label period.
For: Chronic Hand EczemaGermany · Poland